1. Liver X Receptors Enhance Epithelial to Mesenchymal Transition in Metastatic Prostate Cancer Cells.
- Author
-
Bouchareb, Erwan, Dallel, Sarah, De Haze, Angélique, Damon-Soubeyrand, Christelle, Renaud, Yoan, Baabdaty, Elissa, Vialat, Marine, Fabre, Julien, Pouchin, Pierre, De Joussineau, Cyrille, Degoul, Françoise, Sanmukh, Swapnil, Gendronneau, Juliette, Sanchez, Phelipe, Gonthier-Gueret, Céline, Trousson, Amalia, Morel, Laurent, Lobaccaro, Jean Marc, Kocer, Ayhan, and Baron, Silvère
- Subjects
EPITHELIAL cells ,LIVER tumors ,RESEARCH funding ,MESENCHYMAL stem cells ,PROSTATE tumors ,CAUSES of death ,IN vivo studies ,XENOGRAFTS ,MANN Whitney U Test ,DESCRIPTIVE statistics ,METASTASIS ,MICE ,CELL lines ,IMMUNOHISTOCHEMISTRY ,GENE expression ,ANIMAL experimentation ,WESTERN immunoblotting ,DATA analysis software ,CELL receptors - Abstract
Simple Summary: As many cancers, prostate cancer is lethal when reaching the metastatic state. Starting from prostate to invade secondary sites, tumour cells undergo structural modifications called epithelial-mesenchymal transition. Molecular mechanisms controlling this phenomenon were studied in vitro and in vivo after modification of LXRs transcription factors activity, which regulate cholesterol metabolism. These studies showed that in a metastatic cell line derived from bone, increased activity of LXR stimulated the EMT processes in vitro and in vivo. We then characterized the associated deregulated genes and identified Amphiregulin as a new target regulated by LXR. The relationship between amphiregulin and EMT was here first reported in prostate cancer and as this protein can be secreted, will be further considered as a possible blood maker for monitoring metastatic occurrence. Prostate cancer (PCa) is one of the most common cancers in men. Metastasis is the leading cause of death in prostate cancer patients. One of the crucial processes involved in metastatic spread is the "epithelial–mesenchymal transition" (EMT), which allows cells to acquire the ability to invade distant organs. Liver X Receptors (LXRs) are nuclear receptors that have been demonstrated to regulate EMT in various cancers, including hepatic cancer. Our study reveals that the LXR pathway can control pro-invasive cell capacities through EMT in prostate cancer, employing ex vivo and in vivo approaches. We characterized the EMT status of the commonly used LNCaP, DU145, and PC3 prostate cancer cell lines through molecular and immunohistochemistry experiments. The impact of LXR activation on EMT function was also assessed by analyzing the migration and invasion of these cell lines in the absence or presence of an LXR agonist. Using in vivo experiments involving NSG-immunodeficient mice xenografted with PC3-GFP cells, we were able to study metastatic spread and the effect of LXRs on this process. LXR activation led to an increase in the accumulation of Vimentin and Amphiregulin in PC3. Furthermore, the migration of PC3 cells significantly increased in the presence of the LXR agonist, correlating with an upregulation of EMT. Interestingly, LXR activation significantly increased metastatic spread in an NSG mouse model. Overall, this work identifies a promoting effect of LXRs on EMT in the PC3 model of advanced prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF